Adaptive Biotechnologies Corp Market Cap ($2.43 Billion)
Market Cap & Net Worth: Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp market cap. Adaptive Biotechnologies Corp (NASDAQ:ADPT) has a market capitalization of $2.43 Billion ($2.43 Billion) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5335 globally and #1791 in its home market, demonstrating a -1.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adaptive Biotechnologies Corp's stock price $25.80 by its total outstanding shares 153779418 (153.78 Million). Also see ADPT cash flow conversion for how efficiently the company converts equity into cash flow.
Adaptive Biotechnologies Corp Market Cap History (2019–2026)
Adaptive Biotechnologies Corp market cap history from 2019 to 2026. Data shows change from $4.60 Billion to $3.97 Billion (-5.88% CAGR). Check ADPT stock price for real-time trading data and today's change.
Index Memberships
Adaptive Biotechnologies Corp is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.09% | #144 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.01% | #610 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.13% | #89 of 263 |
Weight: Adaptive Biotechnologies Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Adaptive Biotechnologies Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adaptive Biotechnologies Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Adaptive Biotechnologies Corp net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
9.02x
Adaptive Biotechnologies Corp's market cap is 9.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $4.60 Billion | $85.07 Million | -$68.61 Million | 54.09x | N/A |
| 2020 | $9.09 Billion | $98.38 Million | -$146.23 Million | 92.43x | N/A |
| 2021 | $4.32 Billion | $154.34 Million | -$207.28 Million | 27.96x | N/A |
| 2022 | $1.17 Billion | $185.31 Million | -$200.19 Million | 6.34x | N/A |
| 2023 | $753.52 Million | $170.28 Million | -$225.25 Million | 4.43x | N/A |
| 2024 | $921.91 Million | $178.96 Million | -$159.49 Million | 5.15x | N/A |
| 2025 | $2.50 Billion | $276.98 Million | -$59.50 Million | 9.02x | N/A |
Competitor Companies of ADPT by Market Capitalization
Companies near Adaptive Biotechnologies Corp in the global market cap rankings as of November 4, 2026. Also see total assets of Adaptive Biotechnologies Corp for a full breakdown of the balance sheet.
Key companies related to Adaptive Biotechnologies Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Adaptive Biotechnologies Corp (2019–2026)
Market capitalization of Adaptive Biotechnologies Corp from 2019 to today. Between 2019 and today, Adaptive Biotechnologies Corp's market cap moved from $4.60 Billion to $ 3.97 Billion, with a yearly change of -5.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.97 Billion | +58.87% |
| 2025 | $2.50 Billion | +170.89% |
| 2024 | $921.91 Million | +22.35% |
| 2023 | $753.52 Million | -35.86% |
| 2022 | $1.17 Billion | -72.77% |
| 2021 | $4.32 Billion | -52.55% |
| 2020 | $9.09 Billion | +97.63% |
| 2019 | $4.60 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Adaptive Biotechnologies Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.43 Billion USD |
| MoneyControl | $2.43 Billion USD |
| MarketWatch | $2.43 Billion USD |
| marketcap.company | $2.43 Billion USD |
| Reuters | $2.43 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diag… Read more